PATRICIA REXER: Open Payments
NPI 1518320621 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,166 in 46 payments from 13 companies in 2025. Trend: 2023 $3,639 · 2024 $3,193 · 2025 $1,166
Food & beverage: $1,160Education: $7
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 18 | $305 |
| AstraZeneca Pharmaceuticals LP | 7 | $241 |
| Regeneron Healthcare Solutions, Inc. | 4 | $152 |
| GENZYME CORPORATION | 2 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $128 |
| Grifols USA, LLC | 1 | $39 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $36 |
| Incyte Corporation | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| GC Biopharma USA, Inc. | 1 | $21 |
Products named: DUPIXENT, NUCALA, TRELEGY ELLIPTA, FASENRA, AIRSUPRA, CUVITRU, HYQVIA, Xembify.
Industry payments across PA — which companies pay providers there.
